Confidence in Concept 2012 - University of Manchester
Lead Research Organisation:
The University of Manchester
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding. It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.
People |
ORCID iD |
| Luke Georghiou (Principal Investigator) |
Publications
Barbolina I
(2016)
Purity of graphene oxide determines its antibacterial activity
in 2D Materials
Cheng A
(2014)
Cartilage repair using human embryonic stem cell-derived chondroprogenitors.
in Stem cells translational medicine
Mohamed TM
(2013)
Development and characterization of a novel fluorescent indicator protein PMCA4-GCaMP2 in cardiomyocytes.
in Journal of molecular and cellular cardiology
Mohamed TM
(2013)
Optimisation and validation of a high throughput screening compatible assay to identify inhibitors of the plasma membrane calcium ATPase pump--a novel therapeutic target for contraception and malaria.
in Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques
Payton A
(2016)
A role for HLA-DRB1*1101 and DRB1*0801 in cognitive ability and its decline with age.
in American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics
Payton A
(2016)
A TOMM40 poly-T variant modulates gene expression and is associated with vocabulary ability and decline in nonpathologic aging.
in Neurobiology of aging
Shellard P
(2020)
A versatile route to edge-specific modifications to pristine graphene by electrophilic aromatic substitution
in Journal of Materials Science
Vidyasagar R
(2016)
Quantitative measurement of blood flow in paediatric brain tumours-a comparative study of dynamic susceptibility contrast and multi time-point arterial spin labelled MRI.
in The British journal of radiology
Wang T
(2019)
Enhanced chondrogenesis from human embryonic stem cells.
in Stem cell research
| Description | MRC Regenerative Medicine Board funding to Professor Susan Kimber |
| Amount | £793,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2014 |
| End | 01/2017 |
| Description | University of Manchester Intellectual Property PoP award to Professor Paul Bishop |
| Amount | £20,589 (GBP) |
| Organisation | University of Manchester |
| Department | Intellectual Property |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 09/2014 |
| End | 01/2015 |
| Description | Collaboration between Elizabeth Cartwright and MRCT |
| Organisation | MRC-Technology |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Scientific validation of hypothesis for PMCA4 as a novel target for treatment of cardiac hypertrophy and heart failure. Optimisation and validation of a high throughput screening compatible assay for the sarcolemmal calcium ATPase pump and initial studies on discovery of new inhibitors. |
| Collaborator Contribution | MRCT have put in place a team to work with us including a project manager, medicinal chemists and a business development manager. Over the next 6 months MRCT will fund additional library screening and assay development. |
| Impact | Collaboration ongoing, no outcomes reported yet. |
| Start Year | 2014 |
| Description | Collaboration between Neil Pendleton and group led by Professor Harold Garner, Virginia Technology Institute |
| Organisation | Virginia Tech |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | DNA to be sent to the USA for in depth analysis that will have both significant consequences in the short term for our project but a key component for future applications. |
| Collaborator Contribution | Analysis of variable number tandem repeats (VNTRs) as part of the NIH 10K genome project. These VNTRs are a major component of the two human specific domains we have analysed in this proposal. |
| Impact | Collaboration ongoing and outputs not yet reported. Expectation that data generated will be used as the basis for future grant applications. |
| Start Year | 2014 |
| Description | Collaboration between Professor Ian Roberts and Bluestone Global Tech |
| Organisation | Bluestone Global Tech |
| Country | United States |
| Sector | Private |
| PI Contribution | Development, optimisation and standardisation of a GO preparation and purification method from commercially produced Graphite Oxide. |
| Collaborator Contribution | Bluestone Global Tech acts as a collaborator in this project manufacturing Graphite Oxide and other materials and providing technical assistance for different aspects of the project. |
| Impact | Ability to control production of GO with flakes of desired lateral size (0.5-15µm). This is a significant achievement allowing reproducible experiments to be undertaken for the first time in this area. |
| Start Year | 2014 |
| Description | Collaboration between Professor Jian Liu and 2D-Tech Ltd on Graphene Biomaterials |
| Organisation | 2-DTech |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Extensive knowledge and expertise in surfactant science and biointerface, enabling optimisation of schemes for batch production of reproducible G and GO samples as aqueous dispersions with excess surfactants removed. This approach opens up further capability for making biocompatible polymeric G and GO composites. |
| Collaborator Contribution | 2D-Tech Ltd is a spin out company of the University of Manchester that has expertise in applications of graphene research and collaborated with the investigator on the G/GO sample production. |
| Impact | Progress in preparation of biocompatible polymeric G and GO nanocomposites. Expectation of application to EPSRC and BBSRC for further grant supports, with 2D-Tech as collaborator |
| Start Year | 2013 |
| Company Name | Opticin Therapeutics |
| Description | Opticin Therapeutics researches and develops protein therapies to treat human diseases with an initial focus on eye diseases such as diabetic retinopathy. |
| Year Established | 2014 |
| Impact | The results of this research have been kept confidential. It is anticipated that a new patent will be filed once the design of the peptide/peptidomimetic has been optimised. |
| Website | http://www.opticin-therapeutics.com |